Canadians are often uncertain about the role and limits of their private insurance coverage. Let’s change that. The slides for this webinar can be viewed at our Slideshare account. For this webinar, we were joined by Suzanne Lepage, private health plan specialist, for a discussion of Canada’s private drug plan marketplace and its overlap with
On November 22nd, CCSN hosted an All Party Cancer Caucus meeting with members of the Ontario legislature at Queen’s Park, Toronto. Present were representatives from patients and medical professionals, CCSN staff and board members, and volunteer Jaymee Maaghop. The meeting raised awareness and launched crucial discussion on the scarcity and disconnection of rehabilitative services in
The Canadian Cancer Survivor Network (CCSN) held their annual Legislative Reception at Queen’s Park On October 26, 2017. The Reception was an opportunity for patients, MPPs and doctors to discuss cancer-associated thrombosis (CAT), and, despite the ongoing election-prep furor in the Ontario Legislature, the turn out to the event surpassed that of previous years. Over 30
It’s time to get excited for #GivingTuesday! The day is a chance for caring individuals to show their support for charities across the North America. It is the biggest single fundraising day next to New Year’s Eve, and it makes so many incredible initiatives possible.
This webinar will tell you what you need to know about clinical trials, their history, and help you prepare for a trial. If you’re currently considering participating in a clinical trial, we hope that this webinar helps to answer many of your questions. In the presentation you’ll learn the difference between different types of clinical
Ottawa, ON – Jackie Manthorne, President and CEO of the Canadian Cancer Survivor Network (CCSN), has spent over twenty years giving a voice to cancer patients, survivors and caregivers. This fall, that dedication was recognised by the Canadian Cancer Action Network (CCAN), which awarded Manthorne the 2017 Jack Shapiro Lifetime Achievement Award at their Annual
Biologic cancer treatments have become incredibly important in oncology, but they can be expensive. Biosimilars are molecules manufactured to replicate the effects of biologics. They give patients and providers a choice and help to drive prices down through competition, but doctors, patients and caregivers need to understand what biosimilars are, what they can do, and
This webinar introduces you to the effects of blood clots on cancer patients. This webinar also provides you with the following information: How and why blood clots effect cancer patients more than the general population Diagnosis and treatment options Resources for more information The presentation is followed by an interactive discussion with participants. Presenter Information Dr.
The purpose of this survey is to provide the Canadian Cancer Survivor Network (CCSN) with insights and perspectives about the use of Avelumab for the treatment of patients with Merkel cell carcinoma. The survey will be open until Oct. 20. The results of our survey are to be submitted in our patient evidence study to the
If you or a loved one has experienced a blood clot after you were diagnosed with cancer or during chemotherapy, you live in Ontario and would like to help CCSN raise awareness about it, please get in touch with CCSN president & CEO Jackie Manthorne at firstname.lastname@example.org. Every year there are 30,000 incidences of cancer-associated